

# Vétoquinol

a Sign of Passion

## EUROPEAN LAUNCH OF NEW NSAID CIMALGEX®

Lure (France), June 14, 2011 – **Vétoquinol announces the European launch of CIMALGEX®, a new treatment for pain and inflammation in dogs.**

Vétoquinol is the European pioneer in non-steroidal anti-inflammatory drugs. Cimalgex® further reinforces the Group's strategic contribution to pain and inflammation management. Optimal efficacy, statistically proven tolerability and ease of use support the indication of Cimalgex® in the treatment of pain and inflammation associated with arthritis and surgery in dogs. Cimalgex® has been developed for the enhanced well-being of the dog hence increasing the satisfaction and ease of mind of veterinarians and owners.



Cimalgex is a new generation treatment whose active molecule is cimicoxib, discovered by Palau Pharma, a biopharmaceutical company focused on the discovery and development of new medicines for the treatment of inflammatory and autoimmune diseases ([www.palaupharma.com](http://www.palaupharma.com)).

Cimicoxib acts in four main ways, as an anti-pyretic, anti-inflammatory, analgesic and decreases oedema. This is the molecule's first use for medicinal therapeutic purposes.

*"This is the first EU market authorization granted to Vétoquinol under a centralized procedure reserved for innovative medicaments. As a result we were granted market authorization in the 27 countries of the European Union, as a challenge successfully taken up by our teams working in R&D, production, project management and marketing."* declared Vétoquinol CEO Matthieu Frechin. *"This launch fits perfectly with our focused strategy and meets a real need in the veterinary market for this target species."*

**About Vétoquinol**

Vétoquinol is an independent veterinary pharmaceutical laboratory serving both the companion and production animal markets. This family-owned group, dedicated exclusively to animal health, is the 10<sup>th</sup> largest animal healthcare laboratory in the world. More than 80% of its revenues are generated outside France.

Vétoquinol's business includes research and development, production and marketing of medicinal and non-medicinal products. Vétoquinol has positioned itself in the curative sector and has developed expertise in three therapeutic fields: anti-infectives, pain/inflammation and cardiology/nephrology.

The Group currently distributes its products in more than one hundred countries throughout Europe, North America and Asia/Pacific, with subsidiaries in 24 countries and a network of 140 distribution partners. The company has more than 1,700 employees worldwide.

For more information: [www.vetoquinol.com](http://www.vetoquinol.com).

**OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.**

For more information, contact:

**VETOQUINOL**

Investor Relations

Marie-Josée AUBRY-ROTA

Tel.: +33 3 84 62 59 88

[relations.investisseurs@vetoquinol.com](mailto:relations.investisseurs@vetoquinol.com)

**KEIMA COMMUNICATION**

Investor relations

Emmanuel DOVERGNE

Tel.: +33 1 56 43 44 63

[emmanuel.dovergne@keima.fr](mailto:emmanuel.dovergne@keima.fr)

Media relations

Sibylle DESCAMPS

Tel.: +33 1 56 43 44 72

[sibylle.descamps@keima.fr](mailto:sibylle.descamps@keima.fr)